Pre-clinical — Organoids & 3D Cultures
Replacing animal testing with New Approach Methodologies (NAMs). The regulatory tailwind is real: the FDA Modernization Act 2.0 (December 2022) eliminated mandatory animal testing for new drugs; CDSCO is following with the Drugs and Cosmetics Amendment Rules. The science is also real: patient-derived organoids predict clinical response with higher accuracy than rodent models in oncology, IBD, and metabolic disease.
What we offer
Apollo patient-derived organoids
Tumor, intestinal, liver, kidney, and lung organoids derived from consented Apollo patients. Each organoid line ships with linked clinical phenotype, genomic data, and longitudinal treatment-response context. Irreplaceable for India-specific drug development.
3D cell cultures & spheroids
High-throughput-compatible 3D culture formats for efficacy and toxicity screening. Compatible with the LabOS Execution Broker for parallel screening across partner CRO sites.
Organ-on-chip & co-culture
Microfluidic models for liver, kidney, gut-blood-barrier, and tumor-immune microenvironment. Partnership-grade access to Emulate, MIMETAS, and TissUse platforms.
Patient-response prediction
Drug screens across panels of patient-derived organoids, with response data fed back into the OmicsOS Learning Agent to refine response-predictive biomarkers.
Where organoids beat animals
| Use case | Why organoids win |
|---|---|
| Oncology efficacy | Patient-derived tumor organoids correlate with clinical response (~85% concordance) vs. xenografts (~50%) |
| Hepatotoxicity | Liver organoids capture human-specific metabolism (CYP variants) that rodents do not |
| Drug repositioning | Rapid screening across patient organoid panels surfaces unexpected indications faster than animal panels |
| Rare disease | Patient-derived organoids from N=1 patients enable mechanism work where no animal model exists |
Engagement
$200K–$1M per program. Typical sprint: 6–9 months from biospecimen consent through drug screen completion and biomarker report. Bundled discounts when paired with a Target Discovery or Drug Discovery sprint.
Organoid line catalog (Apollo-derived)
| Line type | Indications | Linked data |
|---|---|---|
| Tumor organoids | NSCLC, breast, oral, GI | scRNA + WGS + treatment history |
| Liver organoids | NAFLD, DILI screening | CYP variant panel + metabolomics |
| Intestinal / GI | IBD, absorption studies | Microbiome + phenotype |
| Kidney | Nephrotoxicity, rare disease | Longitudinal creatinine trajectory |